VBL and its 'gene ther­a­py' can­cer treat­ment are back — with a peek at PhI­II po­ten­tial

Three years af­ter a brain can­cer fail­ure sent the com­pa­ny reel­ing, VBL Ther­a­peu­tics is tout­ing its first hint of pos­i­tive Phase III re­sults.

The Is­raeli biotech an­nounced its lead drug, VB–111, met an in­ter­im ef­fi­ca­cy bench­mark in a tri­al test­ing it against stan­dard-of-care alone in re­cur­rent, chemother­a­py-re­sis­tant ovar­i­an can­cer.  The pa­tients in the treat­ment arm had a CA-125 re­sponse rate — a mea­sure of can­cer anti­gen of­ten used as a proxy in ovar­i­an can­cer stud­ies and in de­tect­ing ovar­i­an can­cer — at least 10% high­er than those in the con­trol, the in­de­pen­dent re­view de­ter­mined.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER